Clinical Scorecard: Cardiometabolic Index: An Innovative Prognostic Marker for Assessing Recurrent Stroke Risk in Patients with Acute Ischemic Stroke

At a Glance

Key Highlights

• CMI is a reliable prognostic biomarker for predicting adverse cerebrovascular events in AIS patients post-thrombolysis (source needed).
• A high CMI value (≥0.80) correlates with increased risk of major adverse cerebrovascular events (MACEs) (source needed).
• Systemic inflammation partially mediates the predictive effect of CMI on adverse outcomes (source needed).
• CMI outperforms traditional biomarkers in predicting long-term outcomes for AIS patients (source needed).

Guideline-Based Recommendations

Diagnosis

• Utilize CMI as a prognostic marker for assessing recurrent stroke risk (source needed).

Management

• Incorporate CMI in risk stratification and individualized treatment strategies for AIS patients (source needed).

Monitoring & Follow-up

• Monitor CMI values to assess the risk of MACEs in post-thrombolytic therapy patients (source needed).

Risks

• High CMI values are associated with increased risk of recurrent strokes and adverse cerebrovascular events (source needed).

Patient & Prescribing Data

588 patients with Acute Ischemic Stroke who underwent thrombolytic therapy.

CMI reflects both metabolic and inflammatory status, aiding in the optimization of post-discharge care.

Clinical Best Practices

• Employ CMI for comprehensive risk assessment in AIS patients (source needed).
• Consider systemic inflammation markers alongside CMI for better prognostic accuracy (source needed).

Related Resources & Content

• Cardiometabolic Index Study